CAR-T Therapy Shows Promise in Preventing Multiple Myeloma in High-Risk Patients

Apr 21, 2026

Early trial results presented at the American Association for Cancer Research meeting in San Diego show all 20 high-risk smoldering multiple myeloma patients treated with CAR-T cell therapy achieved complete elimination of detectable myeloma cells. The results represent a far deeper response than typically seen in multiple myeloma treatment and are prompting experts like MD Anderson's Ecaterina Dumbrava to consider whether early immune interception can permanently avert active cancer. Currently, Darzalex antibody therapy is the only approved treatment for high-risk smoldering myeloma, but patients often remain on it for years without deep molecular responses and many still progress to active disease within five years. The trial suggests CAR-T therapy could shift cancer treatment from long-term management to true prevention.

CAR-T therapy trial results for smoldering multiple myeloma

▪All 20 patients who received CAR-T therapy in the smoldering multiple myeloma trial no longer had any detectable myeloma cells in their body.
▪Alison Cameron is a 54-year-old anesthesiologist who received CAR-T therapy while on the smoldering multiple myeloma trial.
▪Alison Cameron had been diagnosed with smoldering multiple myeloma and received infusions to keep it from progressing to active multiple myeloma for years.
▪Alison Cameron spent close to a decade fighting to keep her myeloma under control.
▪A CAR-T therapy trial for smoldering multiple myeloma was presented at the American Association for Cancer Research meeting in San Diego on Monday.

Implications for cancer prevention and potential cure

▪The CAR-T therapy trial results for smoldering multiple myeloma represent a far deeper and more complete response than scientists typically expect for multiple myeloma.
▪Ecaterina Dumbrava is a cancer researcher at MD Anderson Cancer Center who did not work on the smoldering multiple myeloma CAR-T therapy study.
▪Ecaterina Dumbrava stated the smoldering multiple myeloma CAR-T therapy results raise the question of whether early immune interception can redefine treatment goals.
▪The smoldering multiple myeloma CAR-T therapy trial results are prompting some experts to consider the possibility that patients have truly had active cancer permanently averted.

Comparison with current standard treatment options

▪Darzalex is currently the only approved therapy for high risk smoldering myeloma.
▪Many patients on Darzalex for high risk smoldering myeloma still progress to active multiple myeloma within five years.
▪Patients on Darzalex for high risk smoldering myeloma can remain on treatment for years without achieving deep molecular responses.
▪Darzalex is an antibody therapy for high risk smoldering myeloma.

Perspective of Cancer researchers and medical experts

▪The CAR-T therapy trial for smoldering multiple myeloma may represent the first successful attempt to permanently avert active cancer development.
▪The smoldering multiple myeloma CAR-T therapy trial results suggest early immune interception could redefine cancer treatment goals.

Perspective of High-risk smoldering myeloma patients

▪Alison Cameron's CAR-T therapy experience represents a potential alternative to nearly a decade of continuous infusion treatments for smoldering myeloma.